Levobat (Levofloxacin)

Levofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This blockade prevents bacterial cells from multiplying, leading to bacterial death. The mechanism provides a bactericidal effect against a broad spectrum of Gram‑positive and Gram‑negative organisms.

The dosage of Levobat is determined by the prescribing clinician based on the specific infection, patient age, renal function, and other clinical factors. Healthcare professionals set the appropriate strength, frequency, and duration of therapy to ensure optimal efficacy and safety.

The safety of Levobat in pregnancy and lactation has not been definitively established. It should be used only when the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the prescribing physician in consultation with the patient.

To order Levobat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and any necessary import documentation.

Levobat (levofloxacin) offers a once‑daily dosing regimen and a broad spectrum of activity similar to other fluoroquinolones like ciprofloxacin. Compared with older agents, levofloxacin often provides higher potency against respiratory pathogens and a more convenient dosing schedule, but the choice of therapy depends on infection type, resistance patterns and patient-specific factors.

Levobat should be stored at ambient temperature below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Levobat is administered orally, typically as a tablet taken with a full glass of water. It may be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any specific dietary considerations.

Serious risks include tendon rupture, especially of the Achilles tendon, QT interval prolongation leading to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and peripheral neuropathy. Patients should be advised to report any sudden joint pain, palpitations, severe rash, or neurological symptoms promptly.

Levobat is contraindicated in patients with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any of the product’s excipients. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, and in patients taking medications that significantly increase the risk of tendon injury or QT prolongation without appropriate monitoring.